Comparative Pharmacology
Head-to-head clinical analysis: CEFOBID versus DURICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOBID versus DURICEF.
CEFOBID vs DURICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking and causing cell lysis.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
2-4 g/day IV/IM divided q12h; severe infections: 6-12 g/day IV divided q8-12h
500 mg to 1 g orally once or twice daily.
None Documented
None Documented
2 hours (prolonged in hepatic impairment and neonates).
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Primarily renal (80-90% unchanged in urine) and biliary (10-20%).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic